News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunacia’s ViroStatics Reports Phase II Data on VS411, an AV-HALT for Treating HIV/AIDS, During the XVIII International AIDS Conference


7/19/2010 9:43:17 AM

SASSARI, Italy & PRINCETON, N.J.--(BUSINESS WIRE)--ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company’s novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.

Read at BioSpace.com

comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES